- My News
- All News
- Most Popular
Helio Health on Friday presented new data that suggest that the Helio Liver Test, a multi-analyte hepatocellular carcinoma (HCC)-specific blood test, provides greater sensitivity and specificity for the detection of early-stage HCC and disease surveillance in high-risk communities compared with current screening modalities. The data were presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
"These positive data provide further evidence of the Helio Liver Test's ability to provide earlier detection with greater accuracy for liver cancer," remarked CEO Kenneth Chahine, adding that "we look forward to advancing development of this important and easy to use test as we work to make it available to patients and healthcare providers who currently have limited options for accurate and sensitive early-stage detection."
More to come.
To ensure you don't miss other Top Stories like these and news on key medtech industry developments, sign up for our free daily e-newsletter here.
Did you like this article?